Biden Administration Proposes March-In Rights Framework for Pharmaceutical Patents in Effort to Lower Drug Prices

On December 7, the Biden administration announced a proposed framework for determining whether the government may exercise its march-in rights to license pharmaceutical patents to third parties if it determines that the price of a covered drug is too high….
By: Fish & Richardson
Previous Story

Implementation of DFS Cybersecurity Amendments Continues as Ransomware Attacks Dominate Headlines

Next Story

European Union Artificial Intelligence Act